3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
6
Temozolomide
4
Radiotherapy
3
Cyclophosphamide
3
Carmustine
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
sargramostim
2
aldesleukin
2
Thalidomide
2
Paclitaxel
2
Gadolinium DTPA
2
Filgrastim
2
Donepezil
2
Biopsy
2
temsirolimus
1
surufatinib
1
plerixafor
1
omburtamab I-131
1
ganitumab
1
gallium Ga 68 dotatate
1
gadobutrol
1
gadobenic acid
1
entinostat
1
cixutumumab
1
carboxyamido-triazole
1
azurin (50-77)
1
antineoplaston AS 2-1
1
antineoplaston A10
1
adavosertib
1
Zoledronic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Genistein
×
Sarcoma
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts